Carey Anders, MD, discusses the scenario of a 34-year-old patient diagnosed with HER2-positive breast cancer, who develops brain metastases after undergoing initial therapy with dual HER2 blockade.
Inavolisib-Based Therapy Boosts Progression-Free Survival in Breast Cancer
Inavolisib-based therapy reaches the primary end point of the phase 3 INAVO120 study among patients with PIK3CA-mutated breast cancer.
Applying Updated Breast Cancer Findings From ASCO to Clinical Practice
Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.
Bria-IMT Regimen Exceeds Survival Data of SOC in Metastatic Breast Cancer
Four of 13 patients with metastatic breast cancer recruited in 2022 for the phase 2 clinical study evaluating Bria-IMT remain in survival follow-up.
Finding a Place for Exercise Oncology in the Treatment of Breast Cancer
Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.
Ultra-Hypofractionated RT Shows Control, Tolerability in Elderly Breast Cancer
Bin Gui, MD, discussed how ultra-hypofractionated radiotherapy may be a convenient treatment option for elderly patients with early breast cancer.
FDA Approves Inavolisib Combo in PIK3CA+ Advanced Breast Cancer
Data from the INAVO120 trial support the approval of the inavolisib combination for those with PIK3CA-mutant breast cancer.